Stock LFMD LIFEMD, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings LifeMD, Inc.

Equities

LFMD

US53216B1044

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
7.84 USD +2.89% Intraday chart for LifeMD, Inc. +0.90% -5.43%
May. 09 Cantor Fitzgerald Adjusts LifeMD's Price Target to $15 From $13, Keeps Overweight Rating MT
May. 08 Transcript : LifeMD, Inc., Q1 2024 Earnings Call, May 08, 2024

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
LIFEMD, INC. Stock LifeMD, Inc.
-5.43% 332M -
VEEVA SYSTEMS INC. Stock Veeva Systems Inc.
+5.91% 32.95B
C
PRO MEDICUS LIMITED Stock Pro Medicus Limited
+20.73% 8.01B
C-
SECTRA AB Stock Sectra AB
+34.25% 4.38B
B-
EVOLENT HEALTH, INC. Stock Evolent Health, Inc.
-29.52% 2.67B
C-
OMNICELL, INC. Stock Omnicell, Inc.
-13.29% 1.5B
B
VERADIGM INC. Stock Veradigm Inc.
-28.02% 1.27B -
C+
LUNIT INC. Stock Lunit Inc.
-30.53% 1.2B -
SIMULATIONS PLUS, INC. Stock Simulations Plus, Inc.
+11.35% 996M
C
B-SOFT CO.,LTD. Stock B-SOFT Co.,Ltd.
-38.17% 864M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. LFMD Stock
  4. Ratings LifeMD, Inc.